MTEM mtem.com: Enterprise Value to EBITDA Ratio

Brandmark of Molecular Templates (MTEM)

Molecular Templates develops drugs based on protein toxins that selectively attack malignant neoplasms. This chart of EV/EBITDA price dynamics for MTEM is currently at . Molecular Templates aims to expand its engineered toxin system to strengthen its position in the biotech sector by developing its current portfolio of targeted biologics through clinical trials.

MTEM Molecular Templates Corp: Company Value to Operating Income Before Depreciation Ratio in the range 07/04/2022 - 11/11/2026

Metric breakdowns and analytics for mtem.com (MTEM)

- stock price and consensus target price:
Stock Quotes Molecular Templates Corp|MTEM - Average Forecast Price
- company stock capitalization data:
Market Valuation Molecular Templates Corporation|MTEM - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Molecular Templates|MTEM - Net Asset Value|Market Value to Book Value Ratio mtem.com|MTEM - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Molecular Templates|MTEM - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Molecular Templates, Inc.|MTEM - Company Cumulative Indebtedness|Debts to Book Capitalization Molecular Templates Corporation|MTEM - Long-Term Liabilities|Company Short-Term Debt Molecular Templates|Quick Liquidity mtem.com
- business earnings and investment ratios data:
MTEM - Final Profit|Expected Profit Molecular Templates|MTEM - Price to Earnings Ratio|Future Price to Earnings Molecular Templates|MTEM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Templates Corporation|MTEM - Operating profit before deduction of amortization|Earnings per share for the last twelve months Molecular Templates|MTEM - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months mtem.com|MTEM - Earnings per share growth in current year|Earnings growth forecast for next year Molecular Templates
General company analysis:Molecular Templates Corp MTEM
Product sample of Molecular Templates Inc

Searching for fundamentally resilient assets requires analyzing business value relative to its ability to generate cash flow. This ratio compares the total enterprise value, including debt, with operating profit before taxes and depreciation, identifying the risk of overpaying for an asset. For Molecular Templates (MTEM), which lacks commercial sales and relies on licenses, the EV/EBITDA multiple serves as an indicator of the speculative valuation of future potential.

Direct competitors

Geron Corp. - Enterprise Value to EBITDA Ratio|Nanobiotix Group (NBTX) - Company Value to EBITDA|BCYC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CTMX (cytomx.com)|perspectivetherapeutics.com (CATX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GNLX (Genelux)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Partners AG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ONCY|EV/EBITDA Multiple LSTA|EV/EBITDA Multiple moleculin.com (MBRX)|Galera Therapeutics, Inc. - Enterprise Value to EBITDA Ratio